Evidence map›Paper›PMID 28178959›Full record

ArticleBMC pulmonary medicine2017

IL-8 predicts early mortality in patients with acute hypercapnic respiratory failure treated with noninvasive positive pressure ventilation.

Brynja Jónsdóttir, Åsa Jaworowski, Carmen San Miguel, Olle Melander

Open access · goldAbstract read
In one paragraph

Article in BMC pulmonary medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Brynja JónsdóttirThe Department of Clinical Sciences Malmo, Faculty of Medicine, Lund University, Lund, Sweden. brynjajo@gmail.com.
Åsa JaworowskiDepartment of Lung- and Allergy Medicine, Skåne University Hospital, Malmö, Sweden.
Carmen San MiguelDepartment of Internal Medicine and Emergency Medicine, Skåne University Hospital, Malmö, Sweden.
Olle MelanderThe Department of Clinical Sciences Malmo, Faculty of Medicine, Lund University, Lund, Sweden.
Skåne University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with Acute Hypercapnic Respiratory Failure (AHRF) who are unresponsive to appropriate medical treatment, are often treated with Noninvasive Positive Pressure Ventilation (NPPV). Clinical predictors of the outcome of this treatment are scarce. Therefore, we evaluated the role of the biomarkers IL-8 and GDF-15 in predicting 28-day mortality in patients with AHRF who receive treatment with NPPV.

methodsThe study population were 46 patients treated with NPPV for AHRF. Clinical and background data was registered and blood samples taken for analysis of inflammatory biomarkers. IL-8 and GDF-15 were selected for analysis, and related to risk of 28-day mortality (primary endpoint) using Cox proportional hazard models adjusted for gender, age and various clinical parameters.

resultsOf the 46 patients, there were 3 subgroup in regards to primary diagnosis: Acute Exacerbation of COPD (AECOPD, n = 34), Acute Heart Failure (AHF, n = 8) and Acute Exacerbation in Obesity Hypoventilation Syndrome (AEOHS, n = 4). There was significant difference in the basic characteristic of the subgroups, but not in the clinical parameters that were used in treatment decisions. 13 patients died within 28 days of admission (28%). The Hazard Ratio for 28-days mortality per 1-SD increment of IL-8 was 3.88 (95% CI 1.86-8.06, p < 0.001). When IL-8 values were divided into tertiles, the highest tertile had a significant association with 28 days mortality, HR 10.02 (95% CI 1.24-80.77, p for trend 0.03), compared with the lowest tertile. This correlation was maintained when the largest subgroup with AECOPD was analyzed. GDF-15 was correlated in the same way, but when put into the same model as IL-8, the significance disappeared.

conclusionIL-8 is a target to explore further as a predictor of 28 days mortality, in patients with AHRF treated with NPPV.

Indexed as

Noninvasive VentilationAcute DiseaseAgedAged, 80 and overBiomarkersFemaleGrowth Differentiation Factor 15HumansHypercapniaInterleukin-8Kaplan-Meier EstimateMaleMiddle AgedProportional Hazards ModelsPulmonary Disease, Chronic ObstructiveRespiratory InsufficiencyBiomarkersCXCL8 protein, humanGDF15 protein, humanGrowth Differentiation Factor 15Interleukin-8Acute Respiratory FailureGrowth Differentiation Factor 15Interleukin-8Noninvasive Positive Pressure VentilationShort-time Mortality

Identifiers

PMID28178959
PMCPMC5299680
OpenAlexW2587304172

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.